Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ASXL1 mutation + ATM mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

ATM mutation (51)

ASXL1 mutation (20)

ATM mutation + IGH mutation (2)

ATM S978fs*12 (2)

EGFR mutation + ATM mutation (2)

ATM PI2629fs* (1)

ATM S1905Ifs*25 + STK11 K262Sfs*25 (1)

ATM biallelic inactivation (1)

ATM biallelic mutation (1)

ATM mutation + CDK12 mutation (1)

ATM L804fs*4 (1)

BRCA1 mutation + ATM mutation (1)

BRCA2 mutation + ATM mutation (1)

CHEK2 mutation + ATM mutation + BRCA2 mutation (1)

EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K (1)

KRAS G12C + ATM wild-type (1)

KRAS mutation + ATM mutation (1)

RET M918T + ATM L804fs*4 + ATM S978fs*12 (1)

TP53 mutation + ATM mutation (1)

ASXL1 G646Wfs*12 (1)

ASXL1 Y588X (1)

ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + ASXL1 mutation (1)

DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + ASXL1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

ATM T2333fs* (0)

ASXL1 G710X (0)

ATM mutation (51)

ASXL1 mutation (20)

ATM mutation + IGH mutation (2)

ATM S978fs*12 (2)

EGFR mutation + ATM mutation (2)

ATM PI2629fs* (1)

ATM S1905Ifs*25 + STK11 K262Sfs*25 (1)

ATM biallelic inactivation (1)

ATM biallelic mutation (1)

ATM mutation + CDK12 mutation (1)

ATM L804fs*4 (1)

BRCA1 mutation + ATM mutation (1)

BRCA2 mutation + ATM mutation (1)

CHEK2 mutation + ATM mutation + BRCA2 mutation (1)

EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K (1)

KRAS G12C + ATM wild-type (1)

KRAS mutation + ATM mutation (1)

RET M918T + ATM L804fs*4 + ATM S978fs*12 (1)

TP53 mutation + ATM mutation (1)

ASXL1 G646Wfs*12 (1)

ASXL1 Y588X (1)

ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + ASXL1 mutation (1)

DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + ASXL1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

ATM T2333fs* (0)

ASXL1 G710X (0)

›

over1year

Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer. (ASCO 2023)

In this exploratory analysis, patients with co-occurring ATMm and ASXL1m showed higher tumor response. This signals potential value from ATM and ASXL1 co-mutation predicting efficacy of Venadaparib in PC and warrants further validation. Clinical trial information: NCT04174716.

over 1 year ago

Clinical • PARP Biomarker • BRCA Biomarker

|

ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • ASXL1 (ASXL Transcriptional Regulator 1) • BRCA (Breast cancer early onset)

|

ATM mutation • ASXL1 mutation • BRCA mutation • ASXL1 mutation + ATM mutation

|

GuardantOMNI

|

venadaparib (NOV 1401)